AIM:To evaluate the safety and efficacy of the bioartificial liver support system in canines with acute liver failure (ALF). METHODS: Nine canines with acute liver failure by acetaminophen-induced received TECA-I bioartificial liver support system (BALSS) from Hong Kong TECA LTD Co. Blood was perfused through a hollow fiber tube containing (1-2)X10(10) the porcine hepatocytes.In contrast, another 10 canines with acute liver failure by Acetaminophen received drugs. Each treatment lasted 6 hours. RESULTS: BALSS treatment resulted in beneficial effects for acetaminophen-induced ALF canines with survival and with the recovery of the liver functions and tissues, and plasma ammonia decreased from 135.9&mgr;mol/L plus minus 17.5&mgr;mol/L to 65.7&mgr;mol/L plus minus 22.0&mgr;mol/L, 32.5&mgr;mol/L plus minus 8.8&mgr;mol/L, GPT from 97.8U/L plus minus 8.7U/L to 64.8U/L plus minus 11.9U/L, 19.0U/L plus minus 6.3U/L, GOT from 103.0U/L plus minus 16.7U/L to 75.7U/L plus minus 19.6U/L, 26.5U/L plus minus 5.0U/L, and AKP from 158.3U/L plus minus 12.1U/L to 114.5U/L plus minus 19.8U/L, 43.8U/L plus minus 5.6U/L during and after the treatment. In contrast, 10 ALF canines in both the drug and control groups died 1 or 2 days after treatment. CONCLUSION: TECA-1 artificial liver support system is safe and efficacious for canines with acute liver failure.
AIM:To evaluate the safety and efficacy of the bioartificial liver support system in canines with acute liver failure (ALF). METHODS: Nine canines with acute liver failure by acetaminophen-induced received TECA-I bioartificial liver support system (BALSS) from Hong Kong TECA LTD Co. Blood was perfused through a hollow fiber tube containing (1-2)X10(10) the porcine hepatocytes.In contrast, another 10 canines with acute liver failure by Acetaminophen received drugs. Each treatment lasted 6 hours. RESULTS: BALSS treatment resulted in beneficial effects for acetaminophen-induced ALFcanines with survival and with the recovery of the liver functions and tissues, and plasma ammonia decreased from 135.9&mgr;mol/L plus minus 17.5&mgr;mol/L to 65.7&mgr;mol/L plus minus 22.0&mgr;mol/L, 32.5&mgr;mol/L plus minus 8.8&mgr;mol/L, GPT from 97.8U/L plus minus 8.7U/L to 64.8U/L plus minus 11.9U/L, 19.0U/L plus minus 6.3U/L, GOT from 103.0U/L plus minus 16.7U/L to 75.7U/L plus minus 19.6U/L, 26.5U/L plus minus 5.0U/L, and AKP from 158.3U/L plus minus 12.1U/L to 114.5U/L plus minus 19.8U/L, 43.8U/L plus minus 5.6U/L during and after the treatment. In contrast, 10 ALFcanines in both the drug and control groups died 1 or 2 days after treatment. CONCLUSION: TECA-1 artificial liver support system is safe and efficacious for canines with acute liver failure.
Authors: J Rozga; L Podesta; E LePage; E Morsiani; A D Moscioni; A Hoffman; L Sher; F Villamil; G Woolf; M McGrath Journal: Ann Surg Date: 1994-05 Impact factor: 12.969
Authors: J Rozga; M D Holzman; M S Ro; D W Griffin; D F Neuzil; T Giorgio; A D Moscioni; A A Demetriou Journal: Ann Surg Date: 1993-05 Impact factor: 12.969
Authors: A A Demetriou; J Rozga; L Podesta; E Lepage; E Morsiani; A D Moscioni; A Hoffman; M McGrath; L Kong; H Rosen Journal: Scand J Gastroenterol Suppl Date: 1995
Authors: T D Sielaff; M Y Hu; B Amiot; M D Rollins; S Rao; B McGuire; J R Bloomer; W S Hu; F B Cerra Journal: J Surg Res Date: 1995-07 Impact factor: 2.192
Authors: Y L Xue; S F Zhao; Y Luo; X J Li; Z P Duan; X P Chen; W G Li; X Q Huang; Y L Li; X Cui; D G Zhong; Z Y Zhang; Z Q Huang Journal: World J Gastroenterol Date: 2001-12 Impact factor: 5.742